Shares for San Diego-based Quidel Corp. rose about 4 percent after it received U.S. Food and Drug Administration clearance for a new streptococcus A test.

Quidel received 510(k) clearance for the new test, called the Sofia Strep A fluorescent immunoassay, allowing the company to market and sell it across the United States.

Stock for Quidel, an $856 million market cap company, was trading at $25.39 at market close on June 21.

— SDBJ Staff Report